Allergen-specific Immunoglobulin E recognizing Dermatophagoides farinae Der f 1 and Der f 2 epitopes (Der f 1/2-specific IgE)

Allergen-specific Immunoglobulin E (IgE) recognizing Dermatophagoides farinae Der f 1 and Der f 2 epitopes is a primary driver of allergic sensitization to the American house dust mite. Der f 1 is a 25 kDa cysteine protease that facilitates allergen penetration by cleaving epithelial tight junctions, while Der f 2 is a 14 kDa protein that acts as a functional mimic of MD-2, enhancing lipopolysaccharide-induced TLR4 signaling (PMID: 24502325). These IgE antibodies, once produced, sensitize mast cells and basophils by binding to the high-affinity FcεRI receptor. Subsequent exposure to the specific Der f 1 or Der f 2 epitopes causes IgE cross-linking, leading to the rapid release of histamine and other pro-inflammatory mediators responsible for allergic rhinitis and asthma (PMID: 30244776). Therapeutic targeting of this molecule involves the use of Omalizumab, a monoclonal antibody that sequesters free IgE and prevents its binding to FcεRI (PMID: 12847482). Furthermore, allergen-specific immunotherapy (AIT) utilizes extracts containing these epitopes to reprogram the immune system, promoting the development of regulatory T cells and the production of IgG4 blocking antibodies that compete with IgE (PMID: 28434615). Clinical management relies on measuring these specific IgE levels to confirm diagnosis and monitor the efficacy of immunotherapy.

Other names

House dust mite-specific IgEHDM-specific IgEAnti-Der f 1 IgEAnti-Der f 2 IgEDermatophagoides farinae-specific IgE

Sequestration of circulating IgE to prevent binding to high-affinity FcεRI receptors and induction of immune tolerance via allergen-specific immunotherapy.